UBS Starts AbCellera Biologics (ABCL) at Buy

October 12, 2026 2:19 AM EDT Send to a Friend
UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Buy rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login